BETHESDA, MD--(Marketwired - Sep 26, 2014) - Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX), a developer of advanced medical cannabis therapies, announces that it has achieved Good Manufacturing Practices (GMP) capabilities as the Company moves toward the launch of its first clinical study of Cannabics SR capsules.

GMP regulations are designed to ensure that products are produced and controlled according to quality standards. Adhering to these practices ranks Cannabics' products among a very limited number of medical cannabis products available in the U.S. market that are manufactured according to GMP standards.

"We're proud to announce GMP standing as we prepare for the upcoming launch of our Cannabics SR capsules," stated Cannabics' Chief Technology Officer Dr. Eyal Ballan. "We have developed a product with incredible potential in the oncology market and aim to maintain product integrity throughout the entire manufacturing process."

Advancing on its goal to be one of the first and few companies in the world to commercialize clinically tested cannabis-based products, Cannabics intends to launch a series of clinical studies in leading medical centers in Israel where the Company's R&D division is strategically located.

"Cannabics SR, our first market ready product, was developed and designed specifically as a palliative therapy for oncology patients," said Dr. Ballan. "We are still developing a broad pipeline of additional cannabis based products designed for various indications such as Neuropathic pain, inflammatory bowel disease, post trauma stress syndrome, CNS degenerative disorders and more. Each of these products will be tested in comprehensive and formal clinical studies to prove its efficacy and safety."

The efficacy and safety data collected in these formal post-marketing clinical studies, together with the superior pharmacokinetic profile of the Cannabics SR formulation, will be the key advantage of Cannabics products over competing medical cannabis products available in the market.

Cannabics plans to market Cannabics SR capsules under the current medical cannabis regulations in the United States, Europe and Israel. Based on a proprietary formulation that contains only certified food ingredients, Cannabics SR capsules will be marketed as a "cannabis-infused edible product" and will be available to certified and registered patients.

In previous observational studies, Cannabics SR capsules have demonstrated efficiency to provide 10-12 hours of reduced nausea and pain while promoting appetite for cancer patients. Cannabics SR capsules are administered orally one to two times a day, thus providing a convenient administration regimen that increases patients' compliance and avoids the long-term harmful effects of smoking cannabis.

"Cannabics SR capsules answer a considerable unmet need to alleviate the discomforts of oncology patients without the health hazards associated with smoking cannabis for palliative purpose," stated Dr. Ballan. "To date, more than 100 patients in Israel (most of them oncology patients) have already been treated with Cannabics SR capsules. The positive responses and high satisfaction level of patients and doctors with this cannabis based therapy option has been overwhelming."

About Cannabics Pharmaceuticals, Inc.:

Cannabics Pharmaceuticals, Inc. is an emerging drug development company focused on the development and commercialization of advanced drugs, therapies, food supplements and administration routes based on the wide range of active ingredients found in diverse and unique strains of the Cannabis plant. Cannabics' current flagship product is CANNABICS SR -- an IP pending medical cannabis capsule designed specifically for cancer patients as a palliative care treatment. Cannabics' proprietary SR technology provides 10-12 hours of steady state and beneficial therapeutic effects profile, and thus allows for a convenient oral, once-per-day or twice-per-day dosing regimen of medical cannabis for patients. Cannabics is now preparing to launch its line of SR products in eligible states of the US and EU markets under existing medical cannabis regulatory pathways, while simultaneously preparing to launch a series of formal clinical studies in order to establish the unique medical benefits of its products for patients suffering from various indications.

For more information, visit


Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July 15th, 2014. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

For more information, visit:

Contact Information:

Cannabics Pharmaceuticals, Inc.
Itamar Borochov
Corporate VP Marketing